CN107376036B - A method for constructing an enzyme-responsive multifunctional nanocoating - Google Patents
A method for constructing an enzyme-responsive multifunctional nanocoating Download PDFInfo
- Publication number
- CN107376036B CN107376036B CN201710487281.1A CN201710487281A CN107376036B CN 107376036 B CN107376036 B CN 107376036B CN 201710487281 A CN201710487281 A CN 201710487281A CN 107376036 B CN107376036 B CN 107376036B
- Authority
- CN
- China
- Prior art keywords
- solution
- enzyme
- sample
- responsive
- steps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002103 nanocoating Substances 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 29
- 102000004190 Enzymes Human genes 0.000 title claims abstract description 26
- 108090000790 Enzymes Proteins 0.000 title claims abstract description 26
- 108090001008 Avidin Proteins 0.000 claims abstract description 24
- 239000002105 nanoparticle Substances 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 17
- 238000000576 coating method Methods 0.000 claims abstract description 15
- 239000011248 coating agent Substances 0.000 claims abstract description 14
- 229920000669 heparin Polymers 0.000 claims abstract description 14
- 229910001220 stainless steel Inorganic materials 0.000 claims abstract description 11
- 239000010935 stainless steel Substances 0.000 claims abstract description 11
- 229960003638 dopamine Drugs 0.000 claims abstract description 9
- 239000012154 double-distilled water Substances 0.000 claims description 25
- 229920001184 polypeptide Polymers 0.000 claims description 15
- 229920002873 Polyethylenimine Polymers 0.000 claims description 14
- 229920001690 polydopamine Polymers 0.000 claims description 11
- 238000010276 construction Methods 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims description 9
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000003431 cross linking reagent Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 5
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 claims description 5
- 229960001008 heparin sodium Drugs 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000004506 ultrasonic cleaning Methods 0.000 claims description 5
- 230000004044 response Effects 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims 11
- 238000004140 cleaning Methods 0.000 claims 3
- 238000002791 soaking Methods 0.000 claims 3
- 230000010355 oscillation Effects 0.000 claims 1
- 239000008055 phosphate buffer solution Substances 0.000 claims 1
- 238000005498 polishing Methods 0.000 claims 1
- 238000009210 therapy by ultrasound Methods 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
- 239000000463 material Substances 0.000 abstract description 31
- 102000006573 Chemokine CXCL12 Human genes 0.000 abstract description 12
- 108010008951 Chemokine CXCL12 Proteins 0.000 abstract description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract description 10
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 abstract description 10
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 abstract description 10
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract description 9
- 230000003511 endothelial effect Effects 0.000 abstract description 9
- 229960002897 heparin Drugs 0.000 abstract description 9
- 229960002685 biotin Drugs 0.000 abstract description 5
- 235000020958 biotin Nutrition 0.000 abstract description 5
- 239000011616 biotin Substances 0.000 abstract description 5
- 230000027455 binding Effects 0.000 abstract description 3
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 230000003993 interaction Effects 0.000 abstract description 3
- 230000008929 regeneration Effects 0.000 abstract description 3
- 238000011069 regeneration method Methods 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 2
- 210000004369 blood Anatomy 0.000 abstract description 2
- 210000003038 endothelium Anatomy 0.000 abstract description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 abstract 1
- -1 and finally Proteins 0.000 abstract 1
- 230000010100 anticoagulation Effects 0.000 abstract 1
- 239000007822 coupling agent Substances 0.000 abstract 1
- 229910052719 titanium Inorganic materials 0.000 abstract 1
- 239000010936 titanium Substances 0.000 abstract 1
- 230000006872 improvement Effects 0.000 description 14
- 239000004971 Cross linker Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 7
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 7
- 210000000130 stem cell Anatomy 0.000 description 7
- 208000024248 Vascular System injury Diseases 0.000 description 6
- 208000012339 Vascular injury Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 230000008827 biological function Effects 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000005842 biochemical reaction Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000003399 chemotactic effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000003966 vascular damage Effects 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000004151 quinonyl group Chemical group 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
- A61L2300/624—Nanocapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/06—Coatings containing a mixture of two or more compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/08—Coatings comprising two or more layers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种酶响应型纳米涂层的构建方法,首先在多巴胺涂覆的不锈钢表面固定亲和素分子,其次,利用亲和素和生物素之间的特异性识别及结合作用,将生物素化肝素/PEI纳米颗粒固定至材料表面,并进一步用高浓度的亲和素分子与纳米颗粒涂层表面残余的生物素结合,进而引入新的生物素结合位点;然后,继续利用生物素与亲和素之间的相互作用,将生物素化的酶响应多肽组装至纳米颗粒表面,最后,通过EDC/NHS/MES偶联剂将SDF‑1α共价固定于多肽氨基末端,从而构建具有基质金属蛋白酶9响应特性的多功能纳米涂层。本发明在钛表面构建具有抗凝和诱导内皮再生能力的多功能层,显著改善了材料的血液相容性和损伤内皮修复能力。
The invention discloses a method for constructing an enzyme-responsive nano-coating. First, avidin molecules are immobilized on the stainless steel surface coated with dopamine. Biotinylated heparin/PEI nanoparticles were immobilized on the surface of the material, and further high concentrations of avidin molecules were used to bind to the residual biotin on the surface of the nanoparticle coating, thereby introducing new biotin binding sites; Biotinylated enzyme-responsive peptides are assembled on the surface of nanoparticles through the interaction between avidin and avidin, and finally, SDF-1α is covalently immobilized on the amino terminus of the peptide through EDC/NHS/MES coupling agent, thereby constructing Multifunctional nanocoatings with matrix metalloproteinase 9-responsive properties. The invention constructs a multifunctional layer with the ability of anticoagulation and inducing endothelial regeneration on the titanium surface, and significantly improves the blood compatibility of the material and the repairing ability of damaged endothelium.
Description
所属技术领域Technical field
本发明涉及无机材料表面改性技术的技术领域,特别涉及一种酶响应型多功能纳米涂层的构建方法。The invention relates to the technical field of inorganic material surface modification technology, in particular to a construction method of an enzyme-responsive multifunctional nano-coating.
背景技术Background technique
冠心病等心血管疾病严重威胁着人类的生命健康。目前,临床上主要通过金属血管支架介入治疗来改善冠心病患者的血运情况。然而,传统的金属裸支架和药物洗脱支架由于生物相容性不足,在植入后往往会引起中晚期血栓形成和血管内膜增生,进而导致植入失效,甚至危及患者生命安全。Cardiovascular diseases such as coronary heart disease are a serious threat to human life and health. At present, the clinical application of metal vascular stents is mainly used to improve the blood supply of patients with coronary heart disease. However, due to insufficient biocompatibility, traditional bare metal stents and drug-eluting stents often lead to late-stage thrombosis and vascular intimal hyperplasia after implantation, resulting in implantation failure and even endangering the life of patients.
通过对材料表面进行生物化改性,赋予材料良好的抗凝血能力和诱导内皮再生能力是目前常用的提高材料生物相容性的方法。然而,在体内复杂环境下,很多生物涂层难以保持长期的功能,而是在体内动态环境下快速失去其生物学活性。为了实现生物修饰层长期有效的发挥其功能,需要针对其所处的生物学环境进行特定的设计。By biochemically modifying the surface of the material, it is a commonly used method to improve the biocompatibility of the material to endow the material with good anticoagulant ability and the ability to induce endothelial regeneration. However, in the complex environment in vivo, many biocoatings are difficult to maintain long-term functions, but rapidly lose their biological activities in the dynamic environment in vivo. In order to realize the long-term and effective function of the biological modification layer, it needs to be specially designed for the biological environment in which it is located.
肝素是一种临床上广泛使用的抗凝药物,也是心血管材料表面改性所常用的物质。但由于肝素分子缺乏和材料表面直接反应的位点,因此本发明首先在材料表面引入亲和素分子,然后对肝素分子进行生物素化修饰,利用生物素和亲和素之间的特异性结合作用,将肝素分子引入材料表面。为了提高表面肝素的负载量,本发明还引入了一种富含氨基的聚阳离子电解质聚乙烯亚胺,利用生物素化的肝素能与聚乙烯亚胺发生静电交互作用形成纳米颗粒的特性,将纳米颗粒固定到材料表面。Heparin is a widely used anticoagulant drug in clinical practice, and it is also a commonly used substance for surface modification of cardiovascular materials. However, since heparin molecules lack a site for direct reaction with the surface of the material, the present invention first introduces avidin molecules on the surface of the material, and then performs biotinylation modification on the heparin molecules to utilize the specific binding effect between biotin and avidin. , introducing heparin molecules to the surface of the material. In order to increase the loading of surface heparin, the present invention also introduces an amino-rich polycation electrolyte polyethyleneimine, which utilizes the characteristic that biotinylated heparin can interact electrostatically with polyethyleneimine to form nanoparticles. The nanoparticles are anchored to the surface of the material.
间质细胞衍生因子-1α(SDF-1α)是一种对骨髓CXCR4+干细胞及内皮祖细胞(EPCs)具有强烈趋化作用的趋化因子,同时也具有刺激内皮细胞生长,诱导内皮祖细胞向内皮细胞分化的功能。研究表明,SDF-1α能通过诱导内皮祖细胞向血管损伤位点处聚集和分化,加速血管损伤修复和内皮再生。Mesenchymal cell-derived factor-1α (SDF-1α) is a chemokine that has a strong chemotactic effect on bone marrow CXCR4+ stem cells and endothelial progenitor cells (EPCs), and also stimulates endothelial cell growth and induces endothelial progenitor cells to enter the endothelium. function of cell differentiation. Studies have shown that SDF-1α can accelerate vascular injury repair and endothelial regeneration by inducing endothelial progenitor cells to aggregate and differentiate at the site of vascular injury.
PRQITAG多肽是一种对基质金属蛋白酶9(MMP-9)具有特殊响应性的多肽,可在MMP-9存在的条件下发生分解。而MMP-9是血管损伤修复过程中一种重要的功能蛋白,它能快速降解血管基底膜和细胞外基质成分,使其释放多种蛋白质和生长因子,刺激血管细胞的迁移和增殖。因此,MMP-9也可看成是血管损伤修复的信号蛋白。利用这一特点,本发明将具有MMP-9响应特性的PRQITAG多肽作为一种连接分子,将其一端固定在纳米颗粒涂层表面,另一端则连接趋化因子SDF-1α。其目的在于当血管组织受损大量分泌MMP-9时,将诱导材料表面释放SDF-1α分子,加速血管损伤的修复。PRQITAG polypeptide is a polypeptide with special response to matrix metalloproteinase 9 (MMP-9), which can be decomposed in the presence of MMP-9. MMP-9 is an important functional protein in the process of vascular injury repair. It can rapidly degrade the vascular basement membrane and extracellular matrix components, release a variety of proteins and growth factors, and stimulate the migration and proliferation of vascular cells. Therefore, MMP-9 can also be regarded as a signaling protein for vascular injury repair. Taking advantage of this feature, the present invention uses the PRQITAG polypeptide with MMP-9 response properties as a linking molecule, one end of which is fixed on the surface of the nanoparticle coating, and the other end is linked to the chemokine SDF-1α. The purpose is to induce the release of SDF-1α molecules on the surface of the material when the vascular tissue is damaged and secrete a large amount of MMP-9 to accelerate the repair of vascular damage.
这种具有酶响应特性的生物功能层不仅能改善材料表面的血液相容性,同时还可根据血管内环境变化,实现生物分子的按需释放,有效提高了生物分子的利用率和作用时间,促进血管损伤修复。而目前尚无将该种酶响应型纳米涂层心血管材料表面改性的相关报道。This biofunctional layer with enzyme-responsive properties can not only improve the blood compatibility of the material surface, but also realize the on-demand release of biomolecules according to the changes in the intravascular environment, effectively improving the utilization rate and action time of biomolecules. Promotes vascular damage repair. However, there is no relevant report on the surface modification of this enzyme-responsive nano-coating cardiovascular material.
发明内容SUMMARY OF THE INVENTION
本发明的目的在于提供一种酶响应型多功能纳米涂层的构建方法,通过该方法对心血管材料表面进行生物化改性可实现生物因子的按需释放,有效提高材料的生物相容性和促进损伤修复能力;创造性的选择出多功能层的构建方式,并在一定的生物分子浓度比例下,利用各类生物分子间的特异性相互作用,实现功能性生物分子在材料表面的有序组装,进而达到在特定生物环境中,材料表面生物分子按需释放,表面生物功能持续稳定发挥的特性;生物微环境的构建工艺及固定方法均简单易操作,无需昂贵复杂的设备,工艺成本较低,可控制性强,效果显著;不锈钢表面各种生物分子的固定均采用浸泡方式进行,可保证材料各个部分能均匀的固定上生物分子,有利于实现各种结构复杂的心血管植入器械表面的功能化修饰,适用范围广。The purpose of the present invention is to provide a method for constructing an enzyme-responsive multifunctional nano-coating, by which the biochemical modification of the surface of cardiovascular materials can realize the on-demand release of biological factors and effectively improve the biocompatibility of the materials and promote the ability to repair damage; creatively select the construction method of the multifunctional layer, and use the specific interaction between various biomolecules under a certain biomolecule concentration ratio to realize the orderly order of functional biomolecules on the surface of the material Assemble, and then achieve the characteristics that in a specific biological environment, the surface biomolecules are released on demand, and the surface biological functions are continuously and stably exerted; the construction process and fixing method of the biological microenvironment are simple and easy to operate, without expensive and complicated equipment, and the process cost is relatively high. Low, strong controllability and remarkable effect; the fixation of various biomolecules on the stainless steel surface is carried out by immersion, which can ensure that all parts of the material can be evenly fixed with biomolecules, which is conducive to the realization of various cardiovascular implantable devices with complex structures The functional modification of the surface is suitable for a wide range of applications.
本发明实现以上目的采用的技术方案是,一种酶响应型多功能纳米涂层的构建方法,其步骤包含:The technical solution adopted by the present invention to achieve the above object is, a method for constructing an enzyme-responsive multifunctional nanocoating, the steps of which include:
A)316L不锈钢表面经抛光和清洗处理后,浸入浓度为2 mg/ml的多巴胺溶液中反应12小时,双蒸水超声清洗后,重复上述步骤2次,获得沉积有3层聚多巴胺涂层的表面,37℃烘干;A) After the surface of 316L stainless steel was polished and cleaned, it was immersed in a dopamine solution with a concentration of 2 mg/ml for 12 hours. After ultrasonic cleaning with double distilled water, the above steps were repeated twice to obtain three layers of polydopamine coating. surface, drying at 37°C;
B)将A)步骤中沉积聚多巴胺涂层的样品浸泡于0.1~0.5 mg/ml的亲和素溶液中,在37℃条件下静置反应8~24小时,然后用双蒸水清洗样品,保存待用;B) Soak the samples with the polydopamine coating deposited in step A) in 0.1~0.5 mg/ml avidin solution, let them stand for 8~24 hours at 37 °C, and then wash the samples with double distilled water. save for use;
C)将浓度为10~20 mg/ml的生物素化肝素钠溶液与浓度为1~2 mg/ml的聚乙烯亚胺溶液等体积共混,室温下超声处理5分钟,得纳米颗粒悬液。将B步骤中获得的样品浸没于纳米颗粒悬液中,37℃条件下振荡反应8~24小时,然后用双蒸水漂洗样品,保存待用;C) Blend the biotinylated heparin sodium solution with a concentration of 10-20 mg/ml and a polyethyleneimine solution with a concentration of 1-2 mg/ml in equal volumes, and ultrasonically treat it for 5 minutes at room temperature to obtain a nanoparticle suspension . Immerse the sample obtained in step B in the nanoparticle suspension, shake and react at 37°C for 8 to 24 hours, then rinse the sample with double distilled water, and store it for later use;
D)将C)步骤中获得的样品浸没入1~3 mg/ml的亲和素溶液中,37℃条件下反应1~3小时;合成生物素化的酶响应型多肽,其结构为Biotin-PRQITAG-NH2。将上述样品浸泡在10~50μg/ml的多肽溶液中,37℃条件下反应1~3小时后,用双蒸水漂洗样品,保存待用;D) Immerse the sample obtained in step C) into a 1-3 mg/ml avidin solution, and react at 37°C for 1-3 hours; synthesize a biotinylated enzyme-responsive polypeptide whose structure is Biotin- PRQITAG- NH2 . Soak the above samples in 10-50 μg/ml polypeptide solution, react at 37°C for 1-3 hours, rinse the samples with double distilled water, and store them for later use;
E)向浓度为100~500 ng/ml的SDF-1α溶液中滴加摩尔比为2:1:1的EDC/NHS/MES交联剂溶液,混合均匀后立即将D)步骤中获得的样品浸泡其中,37℃条件下反应1~3小时后,用双蒸水清洗样品,即得。E) Add the EDC/NHS/MES crosslinker solution with a molar ratio of 2:1:1 to the SDF-1α solution with a concentration of 100~500 ng/ml dropwise, and immediately mix the sample obtained in D) step Soak in it, react at 37°C for 1 to 3 hours, and wash the sample with double-distilled water.
本发明进一步改进方案是,所述B)、C)、D)、E)步骤中的生物分子溶液,其溶剂均为磷酸盐缓冲液。A further improvement scheme of the present invention is that the biomolecule solutions in the steps B), C), D), and E) are all phosphate buffers as the solvent.
本发明更进一步改进方案是,所述B)、C)、D)、E)步骤中,样品均在表面湿润条件下,在4℃的温度进行冷藏保存。A further improvement scheme of the present invention is that, in the steps B), C), D), and E), the samples are all refrigerated and stored at a temperature of 4°C under the condition of surface wetness.
本发明更进一步改进方案是,所述步骤C)中,聚乙烯亚胺的分子量在60~75kDa的范围内。A further improvement scheme of the present invention is that, in the step C), the molecular weight of polyethyleneimine is in the range of 60-75kDa.
本发明更进一步改进方案是,所述步骤E)中,MES为0.05mol。A further improvement scheme of the present invention is that, in the step E), MES is 0.05mol.
本发明更进一步改进方案是,所述步骤E)中,EDC/NHS/MES交联剂溶液中,A further improvement scheme of the present invention is, in the step E), in the EDC/NHS/MES crosslinking agent solution,
VSDF-1/V交联剂=10/1。V SDF-1 /V crosslinker = 10/1.
参见说明书附图1,本发明的反应过程分包含以下步骤,第一步为不锈钢表面接枝亲和素。首先通过在316L不锈钢表面沉积聚多巴胺涂层,利用多巴胺表面的醌基能与亲和素分子中的氨基发生希夫碱反应的特性,将亲和素固定在材料表面;第二步,利用分子间静电交互作用,合成生物素化肝素/聚乙烯亚胺纳米颗粒;第三步,利用纳米颗粒表面生物素分子能与材料表面亲和素分子特异性识别并结合的特性,将纳米颗粒固定至材料表面;第四步,使用高浓度的亲和素分子来结合纳米涂层表面剩余的生物素分子,同时引入亲和素结合位点;第五步,合成生物素化的基质金属蛋白酶9响应型多肽,利用生物素分子与材料表面亲和素结合位点的特异性识别功能,将多肽固定至材料表面;第六步,使用EDC/NHS/MES交联剂活化SDF-1α分子中的羧基,并与材料表面多肽分子末端的氨基发生脱水缩合反应,从而将SDF-1α固定于材料表面。Referring to Figure 1 of the description, the reaction process of the present invention includes the following steps. The first step is to graft avidin on the stainless steel surface. First, by depositing a polydopamine coating on the surface of 316L stainless steel, the quinone group on the surface of dopamine can react with the amino group in the avidin molecule to undergo Schiff base reaction, and the avidin is immobilized on the surface of the material; the second step, the use of molecular Biotinylated heparin/polyethyleneimine nanoparticles are synthesized by electrostatic interaction between the two; the third step is to fix the nanoparticles to The surface of the material; the fourth step, using a high concentration of avidin molecules to bind the remaining biotin molecules on the nanocoating surface, while introducing avidin binding sites; the fifth step, synthesizing biotinylated matrix metalloproteinase 9 in response to It uses the specific recognition function of the biotin molecule and the avidin binding site on the surface of the material to immobilize the peptide on the surface of the material; the sixth step is to activate the carboxyl group in the SDF-1α molecule with EDC/NHS/MES cross-linking agent , and a dehydration condensation reaction occurs with the amino group at the end of the polypeptide molecule on the surface of the material, thereby immobilizing SDF-1α on the surface of the material.
与现有技术相比,本发明的有益效果是:Compared with the prior art, the beneficial effects of the present invention are:
第一、酶响应型多功能纳米涂层的构建方法,创造性的选择出多功能层的构建方式,并在一定的生物分子浓度比例下,利用各类生物分子间的特异性相互作用,实现功能性生物分子在材料表面的有序组装,进而达到在特定生物环境中,材料表面生物分子按需释放,表面生物功能持续稳定发挥的特性。First, the construction method of the enzyme-responsive multifunctional nanocoating layer creatively selects the construction method of the multifunctional layer, and uses the specific interaction between various biomolecules to realize the function under a certain biomolecule concentration ratio. The orderly assembly of biomolecules on the surface of the material, and then achieve the characteristics that in a specific biological environment, the biomolecules on the surface of the material are released on demand, and the surface biological functions are continuously and stably exerted.
第二、酶响应型多功能纳米涂层的构建方法,生物微环境的构建工艺及固定方法均简单易操作,无需昂贵复杂的设备,工艺成本较低,可控制性强,效果显著。Second, the construction method of the enzyme-responsive multifunctional nanocoating, the construction process of the biological microenvironment and the fixation method are all simple and easy to operate, without the need for expensive and complex equipment, the process cost is low, the controllability is strong, and the effect is remarkable.
第三、酶响应型多功能纳米涂层的构建方法,不锈钢表面各种生物分子的固定均采用浸泡方式进行,可保证材料各个部分能均匀的固定上生物分子,有利于实现各种结构复杂的心血管植入器械表面的功能化修饰,适用范围广。Third, the construction method of the enzyme-responsive multifunctional nano-coating, the immobilization of various biomolecules on the stainless steel surface is carried out by immersion, which can ensure that all parts of the material can be uniformly immobilized on biomolecules, which is conducive to the realization of various complex structures. The functional modification of the surface of cardiovascular implanted devices has a wide range of applications.
附图说明Description of drawings
下面结合附图和实施例对本发明的方法作进一步详细的说明。The method of the present invention will be described in further detail below in conjunction with the accompanying drawings and embodiments.
图1为本发明方法中基质金属蛋白酶9响应型纳米涂层构建的各步骤示意图。(1)316L不锈钢表面多巴胺涂层的沉积和亲和素的组装;(2)生物素化肝素/聚乙烯亚胺纳米颗粒的制备;(3)纳米颗粒在材料表面的固定;(4)纳米颗粒涂层表面组装亲和素分子;(5)生物素化酶响应型多肽在材料表面的组装;(6)SDF-1α在材料表面的固定。Figure 1 is a schematic diagram of each step in the construction of a matrix metalloproteinase 9-responsive nanocoating in the method of the present invention. (1) Deposition of dopamine coating on 316L stainless steel surface and assembly of avidin; (2) Preparation of biotinylated heparin/polyethyleneimine nanoparticles; (3) Immobilization of nanoparticles on the material surface; (4) Nanoparticles Assembly of avidin molecules on the coating surface; (5) assembly of biotinylase-responsive polypeptides on the surface of the material; (6) immobilization of SDF-1α on the surface of the material.
图2为模拟体内流场条件下,MMP9对SDF-1释放动力学的影响结果。Figure 2 shows the effect of MMP9 on the release kinetics of SDF-1 under simulated in vivo flow field conditions.
图3为不同样品表面血小板粘附2小时后的荧光染色结果。Figure 3 shows the fluorescent staining results of platelet adhesion on the surface of different samples for 2 hours.
图4为趋化小室模型中,MMP9存在条件下,酶响应型纳米涂层诱导内皮祖细胞归巢的结果。多巴胺涂层样品为空白对照。Figure 4 shows the results of the homing of endothelial progenitor cells induced by enzyme-responsive nanocoatings in the presence of MMP9 in the chemotactic chamber model. Dopamine-coated samples were blank controls.
具体实施方式Detailed ways
实施例一Example 1
参见图1,本发明的第一种具体实施方式是,一种酶响应型纳米涂层的构建方法,其步骤为:Referring to Fig. 1, a first specific embodiment of the present invention is a method for constructing an enzyme-responsive nanocoating, the steps of which are:
A)316L不锈钢表面经抛光和清洗处理后,浸入浓度为2 mg/ml的多巴胺溶液中反应12小时,双蒸水超声清洗后,重复上述步骤2次,获得沉积有3层聚多巴胺涂层的表面,37℃烘干;A) After the surface of 316L stainless steel was polished and cleaned, it was immersed in a dopamine solution with a concentration of 2 mg/ml for 12 hours. After ultrasonic cleaning with double distilled water, the above steps were repeated twice to obtain three layers of polydopamine coating. surface, drying at 37°C;
B)将A)步骤中沉积聚多巴胺涂层的样品浸泡于0.1 mg/ml的亲和素溶液中,在37℃条件下静置反应8小时,然后用双蒸水清洗样品,保存待用;B) Soak the sample deposited with polydopamine coating in step A) in 0.1 mg/ml avidin solution, let it stand for 8 hours at 37°C, and then wash the sample with double distilled water and save it for use;
C)将浓度为10 mg/ml的生物素化肝素钠溶液与浓度为1 mg/ml的聚乙烯亚胺溶液等体积共混,室温下超声处理5分钟,得纳米颗粒悬液。将B步骤中获得的样品浸没于纳米颗粒悬液中,37℃条件下振荡反应8小时,然后用双蒸水漂洗样品,保存待用;C) The biotinylated heparin sodium solution with a concentration of 10 mg/ml and the polyethyleneimine solution with a concentration of 1 mg/ml were blended in equal volumes, and ultrasonically treated for 5 minutes at room temperature to obtain a nanoparticle suspension. Immerse the sample obtained in step B in the nanoparticle suspension, shake and react at 37°C for 8 hours, then rinse the sample with double distilled water, and save it for later use;
D)将C)步骤中获得的样品浸没入1 mg/ml的亲和素溶液中,37℃条件下反应1小时;合成生物素化的酶响应型多肽,其结构为Biotin-PRQITAG-NH2。将上述样品浸泡在10μg/ml的多肽溶液中,37℃条件下反应1小时后,用双蒸水漂洗样品,保存待用;D) Immerse the sample obtained in step C) into a 1 mg/ml avidin solution, and react at 37°C for 1 hour; synthesize biotinylated enzyme-responsive polypeptide, whose structure is Biotin-PRQITAG-NH 2 . Soak the above samples in 10 μg/ml polypeptide solution, react at 37°C for 1 hour, rinse the samples with double-distilled water, and store them for later use;
E)向浓度为100 ng/ml的SDF-1α溶液中滴加摩尔比为2:1:1的EDC/NHS/MES交联剂溶液,混合均匀后立即将D)步骤中获得的样品浸泡其中,37℃条件下反应1小时后,用双蒸水清洗样品,即得。E) Add dropwise the EDC/NHS/MES crosslinker solution with a molar ratio of 2:1:1 to the SDF-1α solution with a concentration of 100 ng/ml, and immediately soak the sample obtained in step D) in it after mixing evenly , After 1 hour of reaction at 37°C, the sample was washed with double distilled water.
本发明更进一步改进方案是,所述步骤C)中,聚乙烯亚胺的分子量在60~75kDa的范围内。A further improvement scheme of the present invention is that, in the step C), the molecular weight of polyethyleneimine is in the range of 60-75kDa.
本发明更进一步改进方案是,所述步骤E)中,MES为0.05mol。A further improvement scheme of the present invention is that, in the step E), MES is 0.05mol.
本发明更进一步改进方案是,所述步骤E)中,EDC/NHS/MES交联剂溶液中,A further improvement scheme of the present invention is, in the step E), in the EDC/NHS/MES crosslinking agent solution,
VSDF-1/V交联剂=10/1。V SDF-1 /V crosslinker = 10/1.
实施例二
一种酶响应型纳米涂层的构建方法,其步骤为:A method for constructing an enzyme-responsive nano-coating, the steps of which are:
A)316L不锈钢表面经抛光和清洗处理后,浸入浓度为2 mg/ml的多巴胺溶液中反应12小时,双蒸水超声清洗后,重复上述步骤2次,获得沉积有3层聚多巴胺涂层的表面,37℃烘干;A) After the surface of 316L stainless steel was polished and cleaned, it was immersed in a dopamine solution with a concentration of 2 mg/ml for 12 hours. After ultrasonic cleaning with double distilled water, the above steps were repeated twice to obtain three layers of polydopamine coating. surface, drying at 37℃;
B)将A)步骤中沉积聚多巴胺涂层的样品浸泡于0.5 mg/ml的亲和素溶液中,在37℃条件下静置反应8~24小时,然后用双蒸水清洗样品,保存待用;B) Soak the samples with polydopamine coating deposited in step A) in 0.5 mg/ml avidin solution, let stand at 37°C for 8-24 hours, then wash the samples with double distilled water and store them for later use;
C)将浓度为20 mg/ml的生物素化肝素钠溶液与浓度为2 mg/ml的聚乙烯亚胺溶液等体积共混,室温下超声处理5分钟,得纳米颗粒悬液。将B步骤中获得的样品浸没于纳米颗粒悬液中,37℃条件下振荡反应24小时,然后用双蒸水漂洗样品,保存待用;C) The biotinylated heparin sodium solution with a concentration of 20 mg/ml and the polyethyleneimine solution with a concentration of 2 mg/ml were blended in equal volumes, and ultrasonically treated for 5 minutes at room temperature to obtain a nanoparticle suspension. Immerse the sample obtained in step B in the nanoparticle suspension, shake and react at 37°C for 24 hours, then rinse the sample with double distilled water, and save it for use;
D)将C)步骤中获得的样品浸没入3 mg/ml的亲和素溶液中,37℃条件下反应3小时;合成生物素化的酶响应型多肽,其结构为Biotin-PRQITAG-NH2。将上述样品浸泡在50μg/ml的多肽溶液中,37℃条件下反应3小时后,用双蒸水漂洗样品,保存待用;D) Immerse the sample obtained in step C) into a 3 mg/ml avidin solution and react at 37°C for 3 hours; synthesize a biotinylated enzyme-responsive polypeptide whose structure is Biotin-PRQITAG-NH 2 . Soak the above samples in 50 μg/ml polypeptide solution, react at 37°C for 3 hours, rinse the samples with double-distilled water, and store them for later use;
E)向浓度为500 ng/ml的SDF-1α溶液中滴加摩尔比为2:1:1的EDC/NHS/MES交联剂溶液,混合均匀后立即将D)步骤中获得的样品浸泡其中,37℃条件下反应3小时后,用双蒸水清洗样品,即得。E) Add the EDC/NHS/MES crosslinker solution with a molar ratio of 2:1:1 to the SDF-1α solution with a concentration of 500 ng/ml dropwise, and immediately after mixing evenly, soak the sample obtained in step D) in it , after 3 hours of reaction at 37°C, the sample was washed with double distilled water.
本发明更进一步改进方案是,所述步骤C)中,聚乙烯亚胺的分子量在60~75kDa的范围内。A further improvement scheme of the present invention is that, in the step C), the molecular weight of polyethyleneimine is in the range of 60-75kDa.
本发明更进一步改进方案是,所述步骤E)中,MES为0.05mol。A further improvement scheme of the present invention is that, in the step E), MES is 0.05mol.
本发明更进一步改进方案是,所述步骤E)中,EDC/NHS/MES交联剂溶液中,A further improvement scheme of the present invention is, in the step E), in the EDC/NHS/MES crosslinking agent solution,
VSDF-1/V交联剂=10/1。V SDF-1 /V crosslinker = 10/1.
实施例三
一种酶响应型纳米涂层的构建方法,其步骤为:A method for constructing an enzyme-responsive nano-coating, the steps of which are:
A)316L不锈钢表面经抛光和清洗处理后,浸入浓度为2 mg/ml的多巴胺溶液中反应12小时,双蒸水超声清洗后,重复上述步骤2次,获得沉积有3层聚多巴胺涂层的表面,37℃烘干;A) After the surface of 316L stainless steel was polished and cleaned, it was immersed in a dopamine solution with a concentration of 2 mg/ml for 12 hours. After ultrasonic cleaning with double distilled water, the above steps were repeated twice to obtain three layers of polydopamine coating. surface, drying at 37℃;
B)将A)步骤中沉积聚多巴胺涂层的样品浸泡于0.3 mg/ml的亲和素溶液中,在37℃条件下静置反应12小时,然后用双蒸水清洗样品,保存待用;B) Soak the sample with polydopamine coating deposited in step A) in 0.3 mg/ml avidin solution, let it stand at 37°C for 12 hours, then wash the sample with double distilled water and save it for use;
C)将浓度为15 mg/ml的生物素化肝素钠溶液与浓度为1.5 mg/ml的聚乙烯亚胺溶液等体积共混,室温下超声处理5分钟,得纳米颗粒悬液。将B步骤中获得的样品浸没于纳米颗粒悬液中,37℃条件下振荡反应12小时,然后用双蒸水漂洗样品,保存待用;C) An equal volume of biotinylated heparin sodium solution with a concentration of 15 mg/ml and a polyethyleneimine solution with a concentration of 1.5 mg/ml was mixed, and ultrasonically treated at room temperature for 5 minutes to obtain a nanoparticle suspension. Immerse the sample obtained in step B in the nanoparticle suspension, shake and react at 37°C for 12 hours, then rinse the sample with double distilled water, and store it for later use;
D)将C)步骤中获得的样品浸没入2 mg/ml的亲和素溶液中,37℃条件下反应2小时;合成生物素化的酶响应型多肽,其结构为Biotin-PRQITAG-NH2。将上述样品浸泡在30μg/ml的多肽溶液中,37℃条件下反应2小时后,用双蒸水漂洗样品,保存待用;D) Immerse the sample obtained in step C) into a 2 mg/ml avidin solution and react at 37°C for 2 hours; synthesize a biotinylated enzyme-responsive polypeptide whose structure is Biotin-PRQITAG-NH 2 . Soak the above samples in 30 μg/ml polypeptide solution, react at 37°C for 2 hours, rinse the samples with double distilled water, and store them for later use;
E)向浓度为300 ng/ml的SDF-1α溶液中滴加摩尔比为2:1:1的EDC/NHS/MES交联剂溶液,混合均匀后立即将D)步骤中获得的样品浸泡其中,37℃条件下反应2小时后,用双蒸水清洗样品,即得。E) Add dropwise the EDC/NHS/MES crosslinker solution with a molar ratio of 2:1:1 to the SDF-1α solution with a concentration of 300 ng/ml, and immediately soak the sample obtained in step D) in it after mixing evenly , After 2 hours of reaction at 37°C, the sample was washed with double distilled water.
本发明更进一步改进方案是,所述步骤C)中,聚乙烯亚胺的分子量在60~75kDa的范围内。A further improvement scheme of the present invention is that, in the step C), the molecular weight of polyethyleneimine is in the range of 60-75kDa.
本发明更进一步改进方案是,所述步骤E)中,MES为0.05mol。A further improvement scheme of the present invention is that, in the step E), MES is 0.05mol.
本发明更进一步改进方案是,所述步骤E)中,EDC/NHS/MES交联剂溶液中,A further improvement scheme of the present invention is, in the step E), in the EDC/NHS/MES crosslinking agent solution,
VSDF-1/V交联剂=10/1。V SDF-1 /V crosslinker = 10/1.
实施例1相对于实施例3而言,在生物化学反应过程中,合理的缩短反应时间有利于保持生物分子的生物活性,从而更好的发挥其生物学功能;实施例2相对于实施例3而言,根据生物化学反应的机理,最大程度的提高了表面生物分子的装载密度,有利于表面功能更为长期有效的发挥。由此可知,通过实施例1和实施例2得到的纳米涂层的效果均要优于通过实施例3得到的纳米涂层。因此分析效果最差的通过实施例3得到的纳米涂层能够解决本申请所要解决的技术问题的话,那通过实施例1和实施例2也绝对能够解决本申请所要解决的技术问题。Compared with Example 3, in Example 1, in the process of biochemical reaction, a reasonable shortening of the reaction time is conducive to maintaining the biological activity of biomolecules, so as to better exert its biological function; Example 2 is relative to Example 3. In other words, according to the mechanism of biochemical reaction, the loading density of surface biomolecules is increased to the greatest extent, which is beneficial to the longer-term and effective display of surface functions. It can be seen that the effect of the nano-coating obtained by Example 1 and Example 2 is better than that of the nano-coating obtained by Example 3. Therefore, if the nano-coating obtained by Example 3 with the worst analysis effect can solve the technical problem to be solved by this application, then
由图2可知,当材料所处环境中不含MMP9时,材料表面SDF-1的释放很快趋于平缓,表现出较好的稳定性,而当环境中含有MMP9时,可诱导表面纳米涂层的多肽降解,从而控制SDF-1的持续释放。因此,所构建的纳米涂层在体内血流环境中,能在血管损伤释放的信号酶MMP9的刺激下释放SDF-1,促进损伤愈合。It can be seen from Figure 2 that when the material does not contain MMP9 in the environment, the release of SDF-1 on the surface of the material quickly tends to be gentle, showing good stability, while when the environment contains MMP9, the surface nanocoating can be induced. The peptides of the layer are degraded, thereby controlling the sustained release of SDF-1. Therefore, the constructed nanocoating can release SDF-1 under the stimulation of the signaling enzyme MMP9 released by vascular injury in the blood flow environment in vivo, and promote the wound healing.
由图3可知,所构建的纳米涂层能有效降低血小板的粘附和激活,从而避免表面发生凝血或血栓。It can be seen from Figure 3 that the constructed nano-coating can effectively reduce the adhesion and activation of platelets, thereby avoiding coagulation or thrombus on the surface.
由图4可知,构建的纳米涂层在无MMP9存在时,也具有一定的诱导内皮祖细胞归巢和聚集的效果,但并不明显;当有MMP9存在时,纳米涂层表现出显著的诱导内皮祖细胞聚集的效果,这有利于血管损伤后的快速愈合。It can be seen from Figure 4 that the constructed nanocoatings also have a certain effect of inducing the homing and aggregation of endothelial progenitor cells in the absence of MMP9, but it is not obvious; in the presence of MMP9, the nanocoatings show significant induction. The effect of endothelial progenitor cell aggregation, which facilitates rapid healing after vascular injury.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710487281.1A CN107376036B (en) | 2017-06-23 | 2017-06-23 | A method for constructing an enzyme-responsive multifunctional nanocoating |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710487281.1A CN107376036B (en) | 2017-06-23 | 2017-06-23 | A method for constructing an enzyme-responsive multifunctional nanocoating |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107376036A CN107376036A (en) | 2017-11-24 |
| CN107376036B true CN107376036B (en) | 2020-01-07 |
Family
ID=60332034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710487281.1A Active CN107376036B (en) | 2017-06-23 | 2017-06-23 | A method for constructing an enzyme-responsive multifunctional nanocoating |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107376036B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109432515B (en) * | 2018-12-28 | 2020-07-24 | 西南交通大学 | Medical material for inducing tissue repair, preparation method and application thereof |
| CN109701015B (en) * | 2019-01-24 | 2020-12-08 | 华中科技大学 | Structurally stable triangular prism-shaped nano-silver composite probe and its preparation method and application |
| CN114634763B (en) * | 2022-03-21 | 2022-11-11 | 东莞市人民医院 | A kind of cross-linked material with protein coating and preparation method thereof |
| CN118286523B (en) * | 2024-04-02 | 2025-09-23 | 浙江大学 | Preparation method of self-responsive coating for regulating tissue response throughout the entire process of cardiovascular implant interventional devices |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1543339A (en) * | 2001-06-22 | 2004-11-03 | ���Ŵ�ѧ | Porous matrix with cross-linked particles |
| CN101848935A (en) * | 2007-06-06 | 2010-09-29 | 杜门蒂斯有限公司 | Methods for selecting protease resistant polypeptides |
| CN102950102A (en) * | 2012-11-09 | 2013-03-06 | 西南交通大学 | Preparation method of multi-growth-factor slow release coating of titanium and titanium alloy surface |
| CN103599569A (en) * | 2013-11-27 | 2014-02-26 | 天津大学 | Preparation method of titanium alloy surface growth factor composite coating |
| WO2014100377A1 (en) * | 2012-12-20 | 2014-06-26 | Akrivis Technologies, Llc | Mixed payload containing polymers and use therof |
| CN106581742A (en) * | 2016-11-22 | 2017-04-26 | 深圳迈德科技有限公司 | Method of constructing NO catalytic-type nano coating on surface of titanium alloy |
| CN106853265A (en) * | 2017-01-06 | 2017-06-16 | 温州医科大学 | A kind of intelligent anti-bacterial attachment of enzyme response and the LBL self-assembly multilayer coating of sterilization and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7824672B2 (en) * | 2004-03-26 | 2010-11-02 | Emory University | Method for coating living cells |
-
2017
- 2017-06-23 CN CN201710487281.1A patent/CN107376036B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1543339A (en) * | 2001-06-22 | 2004-11-03 | ���Ŵ�ѧ | Porous matrix with cross-linked particles |
| CN101848935A (en) * | 2007-06-06 | 2010-09-29 | 杜门蒂斯有限公司 | Methods for selecting protease resistant polypeptides |
| CN102950102A (en) * | 2012-11-09 | 2013-03-06 | 西南交通大学 | Preparation method of multi-growth-factor slow release coating of titanium and titanium alloy surface |
| WO2014100377A1 (en) * | 2012-12-20 | 2014-06-26 | Akrivis Technologies, Llc | Mixed payload containing polymers and use therof |
| CN103599569A (en) * | 2013-11-27 | 2014-02-26 | 天津大学 | Preparation method of titanium alloy surface growth factor composite coating |
| CN106581742A (en) * | 2016-11-22 | 2017-04-26 | 深圳迈德科技有限公司 | Method of constructing NO catalytic-type nano coating on surface of titanium alloy |
| CN106853265A (en) * | 2017-01-06 | 2017-06-16 | 温州医科大学 | A kind of intelligent anti-bacterial attachment of enzyme response and the LBL self-assembly multilayer coating of sterilization and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| Recent advances in synthetic polymer based hydrogels for spinal cord repair;Thomas Trimaille et al.;《Comptes Rendus Chimie》;20151229;第19卷(第1-2期);第157-166页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107376036A (en) | 2017-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103894328B (en) | The method of the nano particle of laminin and SDF-1 α is taken in the assembling of Ti material surface | |
| CN107376036B (en) | A method for constructing an enzyme-responsive multifunctional nanocoating | |
| JP5722033B2 (en) | Collagen scaffold modified by covalent bonding of graft chains of adhesion molecules and its application to contraction cell tissue engineering and thoracic and cardiovascular therapy | |
| Deng et al. | A collagen–chitosan hydrogel for endothelial differentiation and angiogenesis | |
| US5330911A (en) | Surfaces having desirable cell adhesive effects | |
| CN101310778B (en) | Method for fixing antibody on medical appliance | |
| CN104758985B (en) | A kind of preparation method for the new anticoagulation bracket coating for capturing endothelial progenitor cells EPCs | |
| US8414873B2 (en) | Blood vessel stent of amidoglucosan polysaccharide loaded with CD133 antibody and its preparation method | |
| US5853744A (en) | Solid-phase method for attaching a biomolecule to a substrate surface with a photoreactive crosslinking agent | |
| Liu et al. | Influence of a layer‐by‐layer‐assembled multilayer of anti‐CD34 antibody, vascular endothelial growth factor, and heparin on the endothelialization and anticoagulation of titanium surface | |
| CN104028434B (en) | A kind of method at the laminin/heparin/SDF-1 α anti-freezing of titanium surface construction and inducing endothelial Multifunctional layered | |
| Chen et al. | The fabrication of double-layered chitosan/gelatin/genipin nanosphere coating for sequential and controlled release of therapeutic proteins | |
| CN102698322B (en) | Preparation method of biomedical materials of multiclass functional group rich in amino group, carboxyl group and benzoquinonyl group | |
| CN102058901A (en) | Surface functional titanium material and preparation method thereof | |
| CN104758981A (en) | Growth factor controllable slow-releasing system composite multilayer membrane promoting ossification and preparation method thereof | |
| CN101385870A (en) | A method for improving decellularized tissue engineering valve/vascular stent | |
| Liu et al. | Ulvan mediated VE cadherin antibody and REDV peptide co-modification to improve endothelialization potential of bioprosthetic heart valves | |
| CN107185055A (en) | A kind of surface modifying method of medical magnesium alloy | |
| Liu et al. | Biomimetic modification on the microporous surface of cardiovascular materials to accelerate endothelialization and regulate intimal regeneration | |
| CN101357240A (en) | A method for immobilizing laminin on the surface of Ti-O film | |
| West-Livingston et al. | Antibody-conjugated electrospun vascular scaffolds to enhance in situ endothelialization | |
| CN109735819B (en) | Biomaterial with NO catalytic release and EPCs capture function and preparation method thereof | |
| US8828417B2 (en) | Bioactive coating for an implantable device or bioprosthesis | |
| CN110237312A (en) | A degradable nanocomposite coating loaded with miRNAs and its preparation method and application | |
| CN103785066A (en) | Type I collagen modified porous titanium coat and making method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |